Morningstar - Pendal Group Limited (PDL) Morningstar | Pendal Group Remains our Preferred Asset Manager

Report

Morningstar

John Likos

EUR 850.00 For Business Accounts Only

Morningstar | Pendal Group Remains our Preferred Asset Manager

Pendal Group is a pure-play active fund manager with a strong investment performance record. Domestically, the company benefits from secular growth in compulsory superannuation contributions and favourable demographic trends. Geographic diversification increased significantly following the acquisition of JO Hambro Capital Management in the U.K., providing significantly larger growth opportunities from offshore markets. Meaningful operating leverage will see operating margins strengthen as additional fee income flows through to the bottom line. Stock market performance influences net flows and funds under management, directly affecting revenue and the share price.

07/02/2019 23 EN

Underlying

Pendal Group Limited

Pendal Group is engaged in the provision of investment management services. Co.'s operating segments comprise the investment management business in Australia (BTIM Australia) and outside of Australia (BTIM International). BTIM International comprises the BTIM (UK) Limited group of companies.

See profile

AU0000009789 Australian Securities Exchange Australia

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

John Likos

Other Reports on these Companies

TheScreener

PENDAL GROUP sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of PENDAL GROUP (AU), a company active in the Asset Managers industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date April 5, 2022, the closing price was AUD 5.37 and its potential was estimated at AUD 5.73.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Morningstar

Morningstar | Pendalâ€™s Disappointing 1H19 Prompts FVE Reduction; Magellan and Platinum Under Review

The transition of coverage to a new analyst and a precipitous fall in earnings prompts a reduction in narrow-moat Pendal Groupâ€™s fair value estimate to AUD 8.30 from AUD 10.30 per share. We also place Magellan Financial Group Limited and Platinum Asset Management Limited Under Review while we transition coverage to a new analyst. First-half fiscal 2019 underlying net profit after tax, or NPAT, was 26.6% lower than the previous corresponding period, or pcp. The compounding impact of lower average funds under management, or FUM, and margin contraction exacerbated by historically low performa...

EUR 850.00

May 3, 2019 May 3, 2019 3 EN

Morningstar

Morningstar | Pendalâ€™s Disappointing 1H19 Prompts a Major FVE Reduction

Pendal Group is a pure-play active fund manager with a strong investment performance record. The asset manager boasts a diverse breadth of investment opportunities which appeal to a broader set of investors, thereby providing a differentiating edge over its peers. Geographic diversification increased significantly following the acquisition of JO Hambro Capital Management in the U.K., providing significantly larger growth opportunities from offshore markets. Meaningful operating leverage will see operating margins strengthen as additional fee income flows through to the bottom line. Stock marke...

EUR 850.00

May 3, 2019 May 3, 2019 3 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Joe Gemino

Joe Gemino

Sasol Provides Full-Year Production Update

No-moat Sasol provided an update on its full-year fiscal 2019 production metrics that included relatively stable liquids production. For the full year ended June 30, Sasol produced 1,470 thousand barrels of crude oil and condensate a day compared with 1,469 mboe/d in the year-ago period. However, declines continued with the companyâ€™s natural gas production, down 4% to 130.3 billion cubic feet compared with the period ended June 30, 2018. Sasol also reported flat refined products of 31.4 mmboe/d ...

EUR 100.00

July 25, 2019 July 25, 2019 12 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morningstar | Pendal Group Remains our Preferred Asset Manager

PENDAL GROUP sees an upgrade to Slightly Positive due to a better fundamental star rating

Morningstar | Pendalâ€™s Disappointing 1H19 Prompts FVE Reduction; Magellan and Platinum Under Review

Morningstar | Pendalâ€™s Disappointing 1H19 Prompts a Major FVE Reduction

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Sasol Provides Full-Year Production Update

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe